Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle cell disease. Average Price Target $88 Average recommendation BUY 13 Buy 2 Hold
Company Description Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.